STAAR Surgical Company, together with its subsidiaries, designs, develops, manufactures, markets, and sells implantable lenses for the eye, and delivery systems to deliver the lenses into the eye. The company provides Visian implantable collamer lenses (ICLs) to treat visual disorders, such as myopia, hyperopia, astigmatism, and presbyopia; and Hyperopic ICL, which treats far-sightedness.
Read More…
Industry, Sector and Symbol
Industry Ophthalmic goods
Sub-IndustryHealth Care Supplies
SectorMedical
Phone626-303-7902
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$123.95 million
Profitability
Miscellaneous
Employees475
Next Earnings Date8/7/2019 (Estimated)
OptionableOptionable
STAAR Surgical (NASDAQ:STAA) Frequently Asked Questions
What is STAAR Surgical's stock symbol?
STAAR Surgical trades on the NASDAQ under the ticker symbol "STAA."
How were STAAR Surgical's earnings last quarter?
STAAR Surgical (NASDAQ:STAA) posted its earnings results on Wednesday, May, 1st. The medical instruments supplier reported $0.10 earnings per share (EPS) for the quarter, beating the Thomson Reuters' consensus estimate of $0.04 by $0.06. The medical instruments supplier had revenue of $32.58 million for the quarter, compared to analysts' expectations of $32.40 million. STAAR Surgical had a return on equity of 13.22% and a net margin of 4.44%. During the same period in the previous year, the firm earned $0.01 earnings per share. View STAAR Surgical's Earnings History.
When is STAAR Surgical's next earnings date?
What price target have analysts set for STAA?
2 analysts have issued 12-month price targets for STAAR Surgical's stock. Their forecasts range from $38.00 to $54.00. On average, they anticipate STAAR Surgical's stock price to reach $46.00 in the next twelve months. This suggests a possible upside of 70.2% from the stock's current price. View Analyst Price Targets for STAAR Surgical.
What is the consensus analysts' recommendation for STAAR Surgical?
2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for STAAR Surgical in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for STAAR Surgical.
What are Wall Street analysts saying about STAAR Surgical stock?
Here are some recent quotes from research analysts about STAAR Surgical stock:
- 1. According to Zacks Investment Research, "Staar Surgical Company has evolved to become a developer, manufacturer and global distributor of products used by ophthalmologists and other eye care professionals to improve or correct vision in patients suffering from refractive conditions, cataracts and glaucoma. " (5/7/2019)
- 2. Canaccord Genuity analysts commented, "We view the Warning Letter lift as a bullish catalyst for the stock and the company, with the enormous potential growth engine that is the US market now fully accessible to STAA. While the near term now looks even brighter, we think the firm’s longer-term potential, both with presbyopia (a ~1.5M-patient annual TAM by company estimates) and with full entry into the US market (the second-largest refractive market in the world) acting as major growth drivers – drivers we expect to support sustained, double- digit organic growth into the next decade and beyond. We reiterate our BUY rating and increase our price target to $32 (9.1x EV/sales on 2020E)." (6/20/2018)
Has STAAR Surgical been receiving favorable news coverage?
Media coverage about STAA stock has been trending somewhat positive recently, InfoTrie Sentiment reports. The research group ranks the sentiment of press coverage by analyzing more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. STAAR Surgical earned a news impact score of 1.4 on InfoTrie's scale. They also gave news headlines about the medical instruments supplier a news buzz of 10.0 out of 10, meaning that recent press coverage is extremely likely to have an effect on the stock's share price in the near term. View News Stories for STAAR Surgical.
Who are some of STAAR Surgical's key competitors?
Some companies that are related to STAAR Surgical include Premier (PINC), HYPERA S A/S (HYPMY), Blueprint Medicines (BPMC), Healthequity (HQY), Integra Lifesciences (IART), Healthscope (HSO), Horizon Therapeutics (HZNP), Teladoc Health (TDOC), Hikma Pharmaceuticals (HIK), Globus Medical (GMED), BTG (BTGGF), argenx (ARGX), Wright Medical Group (WMGI), GETINGE AB/ADR (GNGBY) and ABCAM PLC/ADR (ABCZY).
What other stocks do shareholders of STAAR Surgical own?
Who are STAAR Surgical's key executives?
STAAR Surgical's management team includes the folowing people:
- Ms. Caren L. Mason, CEO, Pres & Director (Age 65)
- Ms. Deborah J. Andrews, Chief Financial Officer (Age 62)
- Dr. Keith Holliday, Chief Technology Officer (Age 56)
- Mr. Samuel J. Gesten, Chief Legal Officer & Corp. Sec. (Age 57)
- Mr. Hans-Martin Blickensdoerfer, Sr. VP of Commercial Operations, Direct Markets- Europe & China (Age 54)
Who are STAAR Surgical's major shareholders?
STAAR Surgical's stock is owned by many different of retail and institutional investors. Top institutional investors include Baillie Gifford & Co. (4.01%), Defender Capital LLC. (1.19%), Marshall Wace LLP (0.45%), Hodges Capital Management Inc. (0.38%), Kornitzer Capital Management Inc. KS (0.37%) and King Luther Capital Management Corp (0.34%). Company insiders that own STAAR Surgical stock include Broadwood Partners, LP, Caren L Mason, Deborah J Andrews, Keith Holliday, Samuel J Gesten and William P Wall. View Institutional Ownership Trends for STAAR Surgical.
Which institutional investors are selling STAAR Surgical stock?
STAA stock was sold by a variety of institutional investors in the last quarter, including Acadian Asset Management LLC, SG Americas Securities LLC, PNC Financial Services Group Inc., King Luther Capital Management Corp, Kornitzer Capital Management Inc. KS, Alambic Investment Management L.P., California Public Employees Retirement System and Convergence Investment Partners LLC. Company insiders that have sold STAAR Surgical company stock in the last year include Caren L Mason, Deborah J Andrews, Keith Holliday, Samuel J Gesten and William P Wall. View Insider Buying and Selling for STAAR Surgical.
Which institutional investors are buying STAAR Surgical stock?
STAA stock was acquired by a variety of institutional investors in the last quarter, including Gilder Gagnon Howe & Co. LLC, Baillie Gifford & Co., Marshall Wace LLP, Defender Capital LLC., Cadence Capital Management LLC, Kayne Anderson Rudnick Investment Management LLC, Kayne Anderson Rudnick Investment Management LLC and Robeco Institutional Asset Management B.V.. View Insider Buying and Selling for STAAR Surgical.
How do I buy shares of STAAR Surgical?
Shares of STAA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is STAAR Surgical's stock price today?
One share of STAA stock can currently be purchased for approximately $27.02.
How big of a company is STAAR Surgical?
STAAR Surgical has a market capitalization of $1.20 billion and generates $123.95 million in revenue each year. The medical instruments supplier earns $4.97 million in net income (profit) each year or $0.28 on an earnings per share basis. STAAR Surgical employs 475 workers across the globe.View Additional Information About STAAR Surgical.
What is STAAR Surgical's official website?
How can I contact STAAR Surgical?
STAAR Surgical's mailing address is 25651 ATLANTIC OCEAN DRIVE, LAKE FOREST CA, 92630. The medical instruments supplier can be reached via phone at 626-303-7902 or via email at [email protected]
MarketBeat Community Rating for STAAR Surgical (NASDAQ STAA)
MarketBeat's community ratings are surveys of what our community members think about STAAR Surgical and other stocks. Vote "Outperform" if you believe STAA will outperform the S&P 500 over the long term. Vote "Underperform" if you believe STAA will underperform the S&P 500 over the long term. You may vote once every thirty days.
